Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 3

A review of the role of capecitabine in the treatment of colorectal cancer

Authors Pasquale Comella

Published 15 July 2007 Volume 2007:3(3) Pages 421—431

Pasquale Comella

Department of Medical Oncology, National Tumour Institute, Naples, Italy

Abstract: 5-fluorouracil/leucovorin, with or without oxaliplatin or irinotecan, is the most widely used treatment for the metastatic as well for the adjuvant setting of colorectal cancer. These agents are administered intravenously (by bolus or infusion), thereby causing significant inconvenience to patients. Capecitabine, an oral fluoropyrimidine, has been demonstrated to be at least as effective as bolus 5-fluorouracil/leucovorin in terms of time to disease progression, time to treatment failure, and overall survival, but achieves significantly higher response rates and has the advantage of oral administration. In addition, capecitabine has improved tolerability with a significantly lower incidence of stomatitis, nausea, and alopecia than 5-fluorouracil/leucovorin. Clinical trials have shown that combination therapy with capecitabine and either irinotecan or oxaliplatin is effective and well tolerated. The combination of capecitabine plus oxaliplatin, with or without bevacizumab, could represent the new standard of care for metastatic as well as surgically resected high-risk stage II and III colon cancer patients. Some pharmacoeconomic analyses have highlighted that capecitabine plus oxaliplatin results in cost savings compared with 5-fluorouracil/leucovorin plus oxaliplatin.

Keywords: capecitabine, colon cancer, rectal cancer, adjuvant treatment, combination chemotherapy

Download Article [PDF] 

Readers of this article also read:

Association between homocysteinemia and metabolic syndrome in patients with cardiovascular disease

Chiara Bellia, Giulia Bivona, Concetta Scazzone, Marcello Ciaccio

Therapeutics and Clinical Risk Management 2007, 3:999-1001

Published Date: 15 January 2008

Acute migraine: Current treatment and emerging therapies

Arun A Kalra, Debra Elliott

Therapeutics and Clinical Risk Management 2007, 3:449-459

Published Date: 15 July 2007

Rasagiline – a novel MAO B inhibitor in Parkinson’s disease therapy

Shimon Lecht, Simon Haroutiunian, Amnon Hoffman, Philip Lazarovici

Therapeutics and Clinical Risk Management 2007, 3:467-474

Published Date: 15 July 2007

Recombinant human epoetin beta in the treatment of renal anemia

Francesco Locatelli, Pietro Pozzoni, Lucia Del Vecchio

Therapeutics and Clinical Risk Management 2007, 3:433-439

Published Date: 15 July 2007

A review of rabeprazole in the treatment of acid-related diseases

Fabio Pace, Stefano Pallotta, Stefania Casalini, Gabriele Bianchi Porro

Therapeutics and Clinical Risk Management 2007, 3:363-379

Published Date: 15 July 2007